Module 2: Immunotoxicity Studies: Why, When, and How to Conduct?
Recorded On: 03/27/2025
With the surge of immunotherapies and gene/cell therapies in the past two decades, the need to conduct immunotoxicity studies has increased dramatically. The studies needed for such programs are often case-by-case, and there is little harmonization between organizations. This module focuses on the considerations, principles, and applicable regulatory guidances to design and conduct an immunotoxicity program for major drug modalities.
This eLearning module covers several key areas related to immunotoxicity studies. The module will begin with a review of immunotoxicity testing, highlighting the surge in immunotherapies, gene/cell therapies, and the resulting growing need for immunotoxicity studies. The module will discuss the immunotoxicity assays required to support these programs and how the design differs from traditional immunotoxicity testing. Additionally, the module will provide a brief overview of differences in immune responses between nonclinical species and humans. It will also explore the considerations and applicable regulatory guidances for designing immunotoxicity studies for major drug modalities highlighting the case-by-case nature of these studies and the current lack of harmonization between organizations.
Florence G. Burleson, PhD
Consultant
Burleson Research Technologies, Inc.
Dr. Burleson received her PhD from the Department of Microbiology at the University of Notre Dame and a Master of Science in Financial Management and Technology Commercialization from North Carolina State University (NCSU). She has more than 30 years of professional experience in government, pharmaceutical, and contract research. She is the co-founder of Burleson Research Technologies, Inc. (BRT), a CRO specializing in immunotoxicology. Dr. Burleson has served as a Study Director conducting GLP-compliant studies for immunological, functional, and host resistance immunotoxicity assessments. As Executive VP and Senior Director of Nonclinical Studies, she provides oversight and direction for nonclinical studies programs and is responsible for budgets and financial management at BRT.
Dr. Burleson is a member of the American College of Toxicology (ACT) and Society of Toxicology (SOT), and a Fellow of the Academy of Toxicological Sciences (ATS). She was elected to the ACT Outreach Committee in 2013 and the ACT Council in 2016. She was Vice-President, President-Elect, and President (2022-2023) of ACT. She has also served on the SOT Finance Committee and is a past President of the SOT Immunotoxicology Specialty Section. Dr. Burleson was Chair of the Scientific Liaison Coalition (SLC), a coalition of societies to increase the impact of the science of toxicology to improve public health. She currently serves on the Editorial Board of the International Journal of Toxicology and on the Editorial Board of Toxicology Research Application.
Marie-Soleil Piche, PhD
Scientific Director of the Immunology Group
Charles River Laboratories
Dr. Marie-Soleil Piche is the Scientific Director of the Immunology group at Charles River Laboratories and specializes in nonclinical and clinical immune safety assessment of biotherapeutic drugs. She obtained her Bachelor’s degree in Immunology at McGill University and her Master of Science in Immunotoxicology at the Armand Frappier Institute. She completed a PhD in the field of autoimmune disease, studying the role of autoantibodies in the pathogenesis of lupus. Prior to joining Charles River, Dr. Piche worked at a small biotech company where she was responsible for developing cell-based assays to study the pharmacodynamics of various biotherapeutic drugs. She is an active member of the HELSI/ITC working group, where she co-leads the Education and Outreach group, and of the APPS, where she participates in the Immunogenicity and qPCR working groups. She is also the past president of the ITSS SOT. Dr. Piche is a co-author on several methods, best practices, and validation white papers.